Daxor (DXR) Stock Overview

Engages in medical instrumentation and biotechnology operations. More details

DXR fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	4/6
Financial Health	6/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (11x) is below the US market (18.3x)

Revenue is forecast to grow 120.74% per year

Earnings grew by 246.5% over the past year

Risk Analysis

Earnings are forecast to decline by an average of 138.9% per year for the next 3 years

High level of non-cash earnings

Makes less than USD$1m in revenue ($31K)

Shareholders have been diluted in the past year

+ 1 more risk

DXR Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW424,136 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

424,136 investors already sharing narratives

View all narratives

Daxor Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Daxor
Historical stock prices
Current Share Price	US$11.72
52 Week High	US$14.76
52 Week Low	US$8.56
Beta	0.26
1 Month Change	14.82%
3 Month Change	20.15%
1 Year Change	2.58%
3 Year Change	22.64%
5 Year Change	10.10%
Change since IPO	117.95%

Recent updates

Seeking Alpha • Aug 25

Daxor reports Q2 results

Daxor press release (NASDAQ:DXR): Q2 The increase in revenue of 92.6 percent in the Company’s operating division represents strong strides in the commercialization of its BVA-100. As of June 30, 2022 the company held net assets of $19,615,712 or $4.85 per share, a 35.3 percent increase versus the same period in the prior year.

Seeking Alpha • Jul 21

Daxor partners with Medaxiom to advance awareness of blood volume diagnostic

Daxor (NASDAQ:DXR) said it had partnered with Medaxiom to advance awareness and adoption of Daxor’s blood volume diagnostic. "With heart failure diagnosis continuing to increase, access to accurate blood volume testing will transform the way care decisions are made,” said Joe Sasson, MedAxiom’s EVP of Ventures.

Analysis Article • Mar 08

Daxor's (NASDAQ:DXR) Earnings Aren't As Good As They Appear

We didn't see Daxor Corporation's ( NASDAQ:DXR ) stock surge when it reported robust earnings recently. We decided to...

Analysis Article • Feb 27

A Look At The Fair Value Of Daxor Corporation (NYSEMKT:DXR)

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Daxor Corporation...

Shareholder Returns

	DXR	US Medical Equipment	US Market
7D	8.0%	0.7%	-1.1%
1Y	2.6%	-15.8%	11.7%

Return vs Industry: DXR exceeded the US Medical Equipment industry which returned -16.3% over the past year.

Return vs Market: DXR underperformed the US Market which returned 12.1% over the past year.

Price Volatility

Is DXR's price volatile compared to industry and market?
DXR volatility
DXR Average Weekly Movement	6.9%
Medical Equipment Industry Average Movement	8.2%
Market Average Movement	6.9%
10% most volatile stocks in US Market	15.2%
10% least volatile stocks in US Market	2.9%

Stable Share Price: DXR has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: DXR's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1971	n/a	Michael Feldschuh	www.daxor.com

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973.

Daxor Corporation Fundamentals Summary

How do Daxor's earnings and revenue compare to its market cap?
DXR fundamental statistics
Market cap	US$65.10m
Earnings (TTM)	US$6.23m
Revenue (TTM)	US$31.36k

11.0x

P/E Ratio

2,181x

P/S Ratio

Is DXR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DXR income statement (TTM)
Revenue	US$31.36k
Cost of Revenue	US$0
Gross Profit	US$31.36k
Other Expenses	-US$6.20m
Earnings	US$6.23m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	1.07
Gross Margin	100.00%
Net Profit Margin	19,861.41%
Debt/Equity Ratio	0%

How did DXR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/16 06:30
End of Day Share Price	2026/09/16 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Daxor Corporation is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Frank Takkinen	Lake Street Capital Markets, LLC
Scott Henry	Roth Capital Partners

Daxor (DXR) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Daxor Corporation Competitors

Vaso

Kewaunee Scientific

LENSAR

Jin Medical International

Price History & Performance

Recent News & Updates

New major risk - Revenue and earnings growth

Price target decreased by 14% to US$20.00

Daxor Corporation Initiates Outpatient Blood Volume Analysis Program in Kansas

Insufficient new directors

Daxor Corporation, Annual General Meeting, Jun 23, 2026

Daxor Corporation Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data

Recent updates

New major risk - Revenue and earnings growth

Price target decreased by 14% to US$20.00

Daxor Corporation Initiates Outpatient Blood Volume Analysis Program in Kansas

Insufficient new directors

Daxor Corporation, Annual General Meeting, Jun 23, 2026

Daxor Corporation Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data

Daxor Corporation Showcases Next-Generation Portable Blood Volume Analyzer At ACC.26

Daxor Corporation Showcases New Portable Blood Volume Analyzer

Daxor Corporation Scales Outpatient Presence; Launches BVA Diagnostic Program in Tennessee

Daxor Corporation has completed a Follow-on Equity Offering in the amount of $9.000007 million.

Daxor Corporation has filed a Follow-on Equity Offering in the amount of $9.000007 million.

Daxor Corporation Unveils New FDA-Cleared BVA Analyzer Amid Strong Market Demand and Pivotal Clinical Data at HFSA

Daxor Corporation's Blood Volume Analysis Validated for Covid and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care

Daxor Corporation Receives FDA Clearance for New Rapid, Lightweight, Blood Volume Analysis System

Daxor Corporation, Annual General Meeting, Jun 24, 2025

Daxor Corporation Opens New BVA Program At A Premier Florida Healthcare Center in the Tampa Bay Region

Daxor Corporation Announces New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival

Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer

Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals

Daxor Corporation Announces Multicenter Study Highlights Utility of Daxor's Blood Volume Analysis in Heart Failure Care

Daxor Corporation, Annual General Meeting, Jul 15, 2024

Nasdaq Staff Determines Daxor Complies with Nasdaq’s Audit Committee Requirement Set in Listing Rule 5605

Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion

New minor risk - Profit margin trend

New minor risk - Financial data availability

Daxor Corporation Announces New Data from Duke University Medical Center Validating the Benefits of Blood Volume Analysis

Investor sentiment deteriorates as stock falls 16%

Daxor Corporation Submits Dual 510(K)/CLIA-Waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer

Investor sentiment improves as stock rises 20%

Daxor Corporation Announces the Presentation of Data from a Phase I National Institute of Health Sponsored Randomized Control Trial from Two Veterans Affairs Medical Centers

Daxor Corporation Announces New Data from Banner University Medicine Demonstrating Effectiveness of Bva-100 Use in Ambulatory Heart Failure Patients Presented At Heart Failure Annual Scientific Meeting

JACC-HF Reports Successful Heart Failure Trial with Daxor BVA-100®

Daxor Corporation Announces New Research Letter About Heart Failure Validating the Benefits of BVA-100 Diagnostic in Optimizing Individualized Therapy

Insufficient new directors

Daxor Corporation, Annual General Meeting, Jul 11, 2023

Daxor Corporation has completed a Follow-on Equity Offering in the amount of $4.000035 million.

Investor sentiment deteriorates as stock falls 26%

Investor sentiment improves as stock rises 23%

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Daxor reports Q2 results

Daxor partners with Medaxiom to advance awareness of blood volume diagnostic

Daxor's (NASDAQ:DXR) Earnings Aren't As Good As They Appear

Daxor Corporation Provides Update on American College of Cardiology (ACC) Expert Analysis on the Importance of Addressing Anemia With Blood Volume Analysis in Heart Failure Patients

Daxor Corporation Announces the Initiation of A Multi-Center Clinical Trial with Two Veterans Affairs Medical Centers to Evaluate Blood Volume Analysis Guided Management of Acute Decompensated Heart Failure Utilizing the BVA-100 Blood Test

Daxor Corporation Announces Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Postural Tachycardia Syndrome (POTS)

Daxor Corporation Announces Novel Fluorescent Tracer and Phase-Two US Air Force Contract Award of $750,000 for Point-Of-Care Optical Blood Volume Analyzer

Revenue and earnings miss expectations

A Look At The Fair Value Of Daxor Corporation (NYSEMKT:DXR)

New 90-day low: US$11.49

Daxor Corporation Announces New Data from the University of Hawaii John A. Burns School of Medicine Showing the BVA-100 Blood Test

Daxor Corporation Announces New Distribution Agreement with L1 Enterprises Government Distributor

New 90-day low: US$12.10

New 90-day low: US$12.55

Wake Forest Baptist Health Joins Multicenter Covid-19 Bva-100 Blood Test Study

New 90-day low: US$13.85

New 90-day low: US$14.61

Daxor Corporation Announces Compelling New Data Demonstrating Further Beneficial Use of Blood Volume Analysis Technology Presented During the Heart Failure Society of America’s Virtual Annual Scientific Meeting 2020

Shareholder Returns

Price Volatility

About the Company

Daxor Corporation Fundamentals Summary